Genelux
Genelux
GNLX
NASDAQ
2.17
USD
-0.91%
About
Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens.
Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response.
Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 168.6K |
| Three Month Average Volume | 4.3M |
| High Low | |
| Fifty-Two Week High | 30.44 USD |
| Fifty-Two Week Low | 1.6 USD |
| Fifty-Two Week High Date | 20 Sep 2023 |
| Fifty-Two Week Low Date | 05 Aug 2024 |
| Price and Volume | |
| Current Price | 2.17 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | 18.73% |
| Thirteen Week Relative Price Change | -25.18% |
| Twenty-Six Week Relative Price Change | -72.85% |
| Fifty-Two Week Relative Price Change | -92.84% |
| Year-to-Date Relative Price Change | -86.92% |
| Price Change | |
| One Day Price Change | 9.60% |
| Thirteen Week Price Change | -19.93% |
| Twenty-Six Week Price Change | -70.15% |
| Five Day Price Change | -3.98% |
| Fifty-Two Week Price Change | -91.03% |
| Year-to-Date Price Change | -84.51% |
| Month-to-Date Price Change | 11.28% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.73885 USD |
| Book Value Per Share (Most Recent Quarter) | 1.10533 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.73885 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.10533 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.98463 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.00696 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.00029 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.15832 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.97035 USD |
| Normalized (Last Fiscal Year) | -1.14187 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.15832 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.97035 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.15832 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.97035 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.87993 USD |
| Cash Per Share (Most Recent Quarter) | 0.98699 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.1379 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.95626 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.81148 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -277,788 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -331,725.00% |
| Pretax Margin (Last Fiscal Year) | -16,645.29% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -14,451.18% |
| Operating Margin (Trailing Twelve Months) | -341,437.50% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -16,645.29% |
| Net Profit Margin (Trailing Twelve Months) | -331,725.00% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99.93% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 4.62% |
| EPS Change (Trailing Twelve Months) | -3.56% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 4 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -33,636,000 |
| Net Debt (Last Fiscal Year) | -23,191,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 441 |
| Price to Sales (Trailing Twelve Months) | 9.4K |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 3 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 4 |
| Current Ratio (Most Recent Quarter) | 6 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -21,300,000 |
| Free Cash Flow (Trailing Twelve Months) | -22,223,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -6 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -169.32% |
| Return on Assets (Trailing Twelve Months) | -69.34% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% |
| Return on Equity (Trailing Twelve Months) | -88.57% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -99,999.99% |
| Return on Investment (Trailing Twelve Months) | -84.43% |
| Return on Investment (5 Year) | -99,999.99% |